携癌易感基因致病性胚系变异家族中肺癌的患病率与特征:一项20年回顾性分析
该研究回顾性分析西班牙巴塞罗那医院遗传咨询单元20年间2521个接受胚系检测的家族,其中702个家族为致病性胚系变异携带者,107个家族(15%)有至少1名亲属患肺癌(共130例患者),以DNA修复基因变异者多见。肺癌患者中仅13%接受胚系检测,阳性率88%;67%有多个肿瘤病史。作者认为肺癌在致病性胚系变异携带者亲属中常见,但实践中胚系检测很少进行。
要点
- 702个致病性胚系变异家族中,107个家族(15%)有至少1名亲属患肺癌,共130例患者。
- 肺癌患者中仅13%接受胚系检测,阳性率为88%。
- 67%的肺癌患者有多发肿瘤病史,主要为结直肠癌、黑色素瘤和肺癌。
核心结论
- 肺癌在致病性胚系变异携带者的亲属中常见,但实践中胚系检测很少进行。
- 携带致病性胚系变异的肺癌患者可能具有独特的临床和分子特征。
- 作者认为建立肺癌特异性基因检测标准对于识别可从遗传评估中获益的高危个体是必要的。
研究设计与样本
- 回顾性分析西班牙巴塞罗那医院遗传咨询单元2001年至2021年20年间的临床、分子和胚系遗传数据。
- 共纳入2521个有胚系检测信息的家族,其中702个家族被确定为致病性胚系变异携带者。
主要发现
- 702个致病性胚系变异家族中,107个家族(15%)有至少1名亲属患肺癌,共130例患者,尤其在DNA修复基因变异者中多见。
- 男性占多数,但可获得的病理和分子数据有限。
- 尽管已识别家族性致病性胚系变异,仅13%的肺癌患者接受了胚系检测,其中88%为阳性结果(如BRCA1/2、PALB2、CDKN2A)。
- 67%的肺癌患者有多发肿瘤病史,主要为结直肠癌、黑色素瘤和肺癌。
- 3例致病性胚系变异携带者的肿瘤panel测序揭示了可靶向的驱动突变(如KRAS、EGFR)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Genetic predisposition for lung cancer has historically been underexplored. However, increasing evidence indicates the presence of pathogenic germline variants (PGV) in cancer predisposition genes among patients with lung cancer, highlighting a need for further investigation. Here, we report the prevalence and characteristics of lung cancer in families harboring PGVs studied in our genetic counseling unit (GCU). METHODS: We conducted a retrospective analysis of clinical, molecular, and germline genetic data from patients with lung cancer within families harboring PGVs from the GCU at Hospital Clinic of Barcelona (Spain) over a 20-year period (2001-2021). RESULTS: Of 2521 families with germline testing information, 702 families were identified as PGV carriers. Among these, 107 families (15 %) had ≥ 1 relative with lung cancer (n = 130 patients), particularly in those with PGVs in DNA-repair genes. Males predominated, yet limited pathological and molecular data was available. Despite familial PGV identification, only 13 % of the patients with lung cancer underwent germline testing, with a positive result in 88 % of cases (e.g., BRCA1/2, PALB2, CDKN2A). A significant proportion of them (67 %) had a history of multiple neoplasms, primarily colorectal, melanoma and lung cancer. Tumor panel sequencing in 3 PGV carriers revealed actionable driver mutations (e.g., KRAS, EGFR). CONCLUSIONS: Lung cancer is prevalent among relatives of PGV carriers. However, germline testing is rarely performed in practice. PGV carriers with lung cancer may exhibit distinct clinical and molecular profiles. Establishing specific genetic testing criteria for lung cancer is imperative to identify high-risk individuals who may benefit from genetic assessment.
引用
- Laguna JC, Moreno L, Potrony M, et al. Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysis. Eur J Cancer. 2025. PMID: 40527197. doi:10.1016/j.ejca.2025.115571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。